Miltenyi Biotec, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bergisch Gladbach Germany (1989)
Status: No NME R&D (1989)

Organization Overview

First Clinical Trial
2001
NCT00595127
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Lentigen Technology, Inc. | Miltenyi Biomedicine GmbH | Miltenyi Biotec B.V. & Co. KG | Miltenyi Biotec GmbH | Miltenyi biotech | Miltenyi Biotec, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

omalizumab (xolair) (1 trial)

Drugs in Phase 3 Trials (4)

allogeneic adipose derived mesenchymal stem cell (1 trial)

allogenic t cell-depleted hematopoietic stem cells (1 trial)

autologous cd133+ stem cells (2 trials)

multivirus (cmv, ebv, adv)-specific t cells (1 trial)

Drugs in Phase 2 Trials (29)

aldesleukin (Proleukin) (3 trials)

alemtuzumab (campath) (3 trials)

allogeneic cord blood (1 trial)

allogeneic lymphocytes (1 trial)

anti-cd19/20-car vector-transduced t cells (3 trials)

autologous cd34+ cells (2 trials)

cd19 car-t cells (2 trials)

cd20 car-t cells (2 trials)

cd3,cd19 depleted hematopoietic stem cells (1 trial)

cd3-cd56+ natural killer cells (1 trial)

cyclophosphamide (cytoxan) (3 trials)

cytarabine (cytosar-u) (1 trial)

cytomegalovirus-specific cytotoxic t cells (1 trial)

cytotoxic t cells (1 trial)

fludarabine (fludara) (4 trials)

furosemide (lasix) (1 trial)

gemcitabine (gemzar) (1 trial)

ifnγ- positive selected t-cells (1 trial)

immune globulin (human) (Gamastan) (1 trial)

mesna (mesnex) (1 trial)

naltrexone (revia) (1 trial)

oxaliplatin (eloxatin) (1 trial)

polatuzumab vedotin (Polivy) (1 trial)

rituximab (rituxan) (2 trials)

sargramostim (leukine) (1 trial)

sars-cov-2 specific t cells (1 trial)

sirolimus (rapamune) (2 trials)

tacrolimus (prograf) (2 trials)

tr004 (1 trial)

Drugs in Phase 1 Trials (5)

autologous regulatory t cells (1 trial)

autologous tumor infiltrating lymphocytes (1 trial)

bendamustine (treanda) (1 trial)

cd56-enriched donor lymphocyte (1 trial)

melphalan (alkeran) (1 trial)

Drugs in Other Trials (2)

Key: Miltenyi Biotec, Inc. (1) Acquired (1)

cd8 depleted donor lymphocyte (1 trial)

infliximab (remicade) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anaphylaxis (Phase 4)

Anemia, Aplastic (Phase 2)

Anemia, Sickle Cell (Phase 2)

Carcinoma (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Communicable Diseases (Phase 2)

Coronary Artery Disease (Phase 3)

Crohn Disease (Phase 2)

Cytomegalovirus Infections (Phase 2)

Food Hypersensitivity (Phase 4)

Graft vs Host Disease (Phase 1)

Hodgkin Disease (Phase 1)

Infections (Phase 2)

Ischemia (Phase 3)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 3)

Neoplasms (Phase 3)

Neoplasms, Plasma Cell (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial APIs: 41